Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: The role of treatment order

Medicine & Life Sciences

• human ERBB2 protein 100%
• Hormones 57%
• Breast Neoplasms 52%
• palbociclib 20%
• Cyclin-Dependent Kinase 6 19%
• Cyclin-Dependent Kinase 4 17%
• Therapeutics 13%
• 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide 13%
• Alpelisib 11%
• 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine 11%
• 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 11%
• ribociclib 11%
• NVP-BKM120 10%
• entinostat 10%
• Survival Rate 9%
• exemestane 9%
• Letrozole 8%
• Fulvestrant 8%
• Estrogen Receptor Modulators 8%
• Everolimus 7%
• Oncologists 6%
• Phosphatidylinositol 3-Kinases 6%
• Estrogen Receptors 5%
• Neoplasm Metastasis 3%
• Mutation 3%
• Genes 2%